Autopsy report · NCT02044822
Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion
Cause of deathNo reason given
Life of this trial
- Registered 6 months before it started.
- Ran for about 1 year 9 months before it stopped.
- 102 participants enrolled.
- Results were posted on the registry 1 year after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Gilead Sciences
- Sponsor type
- Industry
- Conditions
- B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion
- Interventions
- Idelalisib; Rituximab
- Participants
- 102
- Sites
- 56
- Countries
- Australia, Austria, Belgium, Czechia, Denmark, France, Hungary, Italy, Poland, Portugal, Romania, Spain and more
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.